Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel

Japanese Journal of Cancer Research

Volumn 92, Issue 2, 2001, Pages 231-238

  Minami, Hironobu ^a   Sasaki, Yasutsuna ^a   Watanabe, Torn ^a   Ogawa, Makoto ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Fever; Leukopenia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

PACLITAXEL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; BONE MARROW; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NEUTROPENIA; PARAMETER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BREAST NEOPLASMS; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; KINETICS; LEUKOCYTE COUNT; LEUKOPENIA; MIDDLE AGED; MODELS, BIOLOGICAL; PACLITAXEL;

EID: 0035076496     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01086.x     Document Type: Article

References (30)

1. Pharmacodynamics in cancer therapy
2. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion
3. Modeling interpatient pharmacodynamic variability of toposide
4. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide
5. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
6. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
7. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
8. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
9. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer
10. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
11. A population model for the leukopenic effect of etoposide
12. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
13. Pharmacodynamic analysis of hematologic profiles
14. Combining physiologic models and symbolic methods to interpret time-varying patient data
15. Indirect-response model for the time course of leukopenia with anticancer drugs
16. Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan
17. Paclitaxel pharmacokinetics and pharmacodynamics
18. Physiologic indirect response models characterize diverse types of pharmacodynamic effects
19. Hematopoietic cellular production
20. Granulocyotopoiesis in human bone marrow cultures studied by means of kinematography
21. 32)
22. Granulocytopoiesis. II. Emergence and pattern of labeling of neutrophilic granulocytes in humans
23. The kinetics of granulopoiesis in normal man
24. Neutrophil kinetics and function
25. The hematopoietic microenvironment in the elderly: Defects in IL-1-induced CSF expression in vitro
26. Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice
27. A comparative study of bone marrow function in young and old individuals
28. Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections
29. Protein binding; assessment and importance
30. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer